457 related articles for article (PubMed ID: 15491291)
1. Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance.
Rajkumar SV; Kyle RA; Therneau TM; Clark RJ; Bradwell AR; Melton LJ; Larson DR; Plevak MF; Katzmann JA
Br J Haematol; 2004 Nov; 127(3):308-10. PubMed ID: 15491291
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the analytical performance and the sensitivity of serum free light chains immunoassay in patients with monoclonal gammopathy.
Wolff F; Thiry C; Willems D
Clin Biochem; 2007 Mar; 40(5-6):351-4. PubMed ID: 17239359
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany.
Eisele L; Dürig J; Hüttmann A; Dührsen U; Assert R; Bokhof B; Erbel R; Mann K; Jöckel KH; Moebus S;
Ann Hematol; 2012 Feb; 91(2):243-8. PubMed ID: 21789623
[TBL] [Abstract][Full Text] [Related]
4. The evolving use of serum free light chain assays in haematology.
Pratt G
Br J Haematol; 2008 May; 141(4):413-22. PubMed ID: 18318757
[TBL] [Abstract][Full Text] [Related]
5. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
[TBL] [Abstract][Full Text] [Related]
6. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.
Rajkumar SV; Kyle RA; Therneau TM; Melton LJ; Bradwell AR; Clark RJ; Larson DR; Plevak MF; Dispenzieri A; Katzmann JA
Blood; 2005 Aug; 106(3):812-7. PubMed ID: 15855274
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of the clinical relevance of serum measurements of free-light chains in patients with multiple myeloma].
Shimizu K; Itoh J; Sugiura I; Tsushita K; Kosugi H; Nagura E
Rinsho Ketsueki; 2006 Apr; 47(4):303-9. PubMed ID: 16715965
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal B-cell disorder.
Vermeersch P; Van Hoovels L; Delforge M; Mariën G; Bossuyt X
Br J Haematol; 2008 Nov; 143(4):496-502. PubMed ID: 18729849
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal gammopathy of undetermined significance (MGUS) in patients with solid tumors: effects of chemotherapy on the monoclonal protein.
Anagnostopoulos A; Galani E; Gika D; Sotou D; Evangelopoulou A; Dimopoulos MA
Ann Hematol; 2004 Oct; 83(10):658-60. PubMed ID: 15278296
[TBL] [Abstract][Full Text] [Related]
10. [Monoclonal gammopathy of undetermined significance].
Chaïbi P; Merlin L; Thomas C; Piette F
Ann Med Interne (Paris); 2002 Nov; 153(7):459-66. PubMed ID: 12598832
[TBL] [Abstract][Full Text] [Related]
11. Can serum free light chains replace urine electrophoresis in the detection of monoclonal gammopathies?
Beetham R; Wassell J; Wallage MJ; Whiteway AJ; James JA
Ann Clin Biochem; 2007 Nov; 44(Pt 6):516-22. PubMed ID: 17961305
[TBL] [Abstract][Full Text] [Related]
12. [Monoclonal gammopathies of undetermined significance].
Krizalkovicová V; Maisnar V; Pour L; Radocha J; Hájek R
Klin Onkol; 2008; 21(4):160-4. PubMed ID: 19102222
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma].
Scudla V; Budíková M; Petrová P; Minarík J; Pika T; Bacovský J; Adamová D; Langová K;
Klin Onkol; 2010; 23(3):171-81. PubMed ID: 20608327
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal gammopathy related to Sjögren syndrome: a key marker of disease prognosis and outcomes.
Brito-Zerón P; Retamozo S; Gandía M; Akasbi M; Pérez-De-Lis M; Diaz-Lagares C; Bosch X; Bové A; Pérez-Alvarez R; Soto-Cárdenas MJ; Sisó A; Ramos-Casals M
J Autoimmun; 2012 Aug; 39(1-2):43-8. PubMed ID: 22297146
[TBL] [Abstract][Full Text] [Related]
15. Use of interval-specific likelihood ratios improves clinical interpretation of serum FLC results for the diagnosis of malignant plasma cell disorders.
Vermeersch P; Vercammen M; Holvoet A; Vande Broek I; Delforge M; Bossuyt X
Clin Chim Acta; 2009 Dec; 410(1-2):54-8. PubMed ID: 19778527
[TBL] [Abstract][Full Text] [Related]
16. [Usefulness of a free light chain immunoassay in serum for the diagnosis and the follow-up of monoclonal gammopathy].
Guenet L; Decaux O; Lechartier H; Ropert M; Grosbois B
Rev Med Interne; 2007 Oct; 28(10):689-97. PubMed ID: 17566612
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.
Kyle RA; Rajkumar SV
Br J Haematol; 2007 Dec; 139(5):730-43. PubMed ID: 18021088
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
19. [Clinical value of the blood measurement of the free light chains of immunoglobulins].
Bidet A; Marit G; Bérard AM
Ann Biol Clin (Paris); 2008; 66(4):427-31. PubMed ID: 18725344
[TBL] [Abstract][Full Text] [Related]
20. Serum free light chains in clinical laboratory diagnostics.
Jenner E
Clin Chim Acta; 2014 Jan; 427():15-20. PubMed ID: 23999048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
